Results 151 to 160 of about 41,944 (264)

Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.

European Journal of Cancer
BACKGROUND The randomized, open-label, phase III LYNK-003 study assessed the efficacy of first-line maintenance olaparib, alone or in combination with bevacizumab, versus bevacizumab plus a fluoropyrimidine in participants with unresectable or metastatic
A. Takashima, P. García-Alfonso, Raimundo Manneh, A. A. Besen, Y. Hong, P. Cuyle, P. Yanez, M. Burge, T. Yoshino, Tae Won Kim, Karen Cui, Chenxiang Li, Rishi Jain, D. Adelberg, J. Taieb   +14 more
semanticscholar   +1 more source

Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents

Chemistry – A European Journal, Volume 32, Issue 17, 5 May 2026.
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley   +1 more source

Anticancer sensitivities and biological characteristics of HCT116 cells resistant to the selective poly(ADP‐ribose) glycohydrolase inhibitor

FEBS Open Bio, Volume 16, Issue 5, Page 1020-1029, May 2026.
We analyzed alterations of PAR metabolism‐related proteins in PARG inhibitor‐resistant HCT116RPDD cells. Although PARG levels remained unchanged, HCT116RPDD cells exhibited reduced PARP1 and ARH3 expression and elevated PAR levels. Interestingly, HCT116RPDD cells exhibited slightly elevated intracellular NAD+/NADH and ATP levels. Our findings suggest a
Kaede Tsuda, Yoko Ogino, Akira Sato
wiley   +1 more source

The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials

Cancer Management and Research, 2018
Xiao Xia Guo,1,* Hong Li Wu,2,* Hong Yun Shi,3 Lei Su,3 Xi Zhang3 1Department of Obstetrics and Gynecology, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, Chengdu, 2Department of Obstetrics and Gynecology, Hebei ...
Guo XX, Wu HL, Shi HY, Su L, Zhang X
doaj  

NAD+‒circadian rhythm coupling in dementia

Alzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract The circadian rhythm system and sleep coordinate whole‐body functions across the 24‐h cycle, yet these rhythms progressively deteriorate with neurodegenerative diseases, including dementia. Growing evidence indicates that nicotinamide adenine dinucleotide (NAD+) interacts with the circadian system through multiple molecular pathways and that ...
Shi‐qi Zhang, Jiyeon Lee, Jun‐ping Pan, Rune Enger, Harald Hrubos‐Strøm, Erik S. Musiek, Evandro Fei Fang, Weidong Le   +7 more
wiley   +1 more source

Concurrent olaparib and radiotherapy in elderly patients with newly diagnosed glioblastoma: the phase I dose escalation PARADIGM trial.

International Journal of Radiation Oncology, Biology, Physics
BACKGROUND Patients with glioblastoma who are elderly or have poor performance status (PS) experience particularly poor clinical outcomes. At the time of study initiation, these patients were treated with short-course radiotherapy (40 Gy in 15 fractions).
S. Derby, M. Jackson, K. Williams, J. Stobo, C. Kelly, L. Sweeting, S. Shad, C. Herbert, S. C. Short, A. Williamson, A. James, S. Nowicki, Helen Bulbeck, A. Chalmers   +13 more
semanticscholar   +1 more source

Integrated Molecular Profiling Improves Subtype Classification and Reveals Inherited Susceptibility in Medulloblastoma: Insights From a Real‐World Cohort

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Medulloblastoma (MB) is a heterogeneous pediatric brain tumor characterized by distinct molecular subtypes. Although genomics and transcriptomics have improved subtype classification and informed targeted therapies, the clinical utility of integrated molecular profiling in real‐world settings remains incompletely defined. Methods We
Jiwei Song, Tiantian Han, Siqi Chen, Dongsheng Chen, Ziying Liu   +4 more
wiley   +1 more source

Germline Pathogenic Variants in HER2‐Positive Breast Cancer: Spectrum and Clinical Implications in a High‐Risk Chinese Cohort

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Objective Hereditary cancer risk assessment has predominantly focused on HER2‐negative breast cancer (BC), with limited characterization of germline pathogenic variants (GPVs) in HER2‐positive disease. This study aimed to delineate the prevalence, clinicopathological correlates, and clinical implications of GPVs in a cohort of HER2‐positive BC
Lijia Zhou, Mengqian Ni, Anli Yang, Qingru Zhou, Daining Wang, Shu Dun, Fei Xu, Jiajia Huang, Xiwen Bi, Wen Xia, Ruoxi Hong, Qiufan Zheng, Meiting Chen, Kuikui Jiang, Jun Tang, Xi Wang, Zhongyu Yuan, Shusen Wang, Yanxia Shi, Fang Wang, Xin An   +20 more
wiley   +1 more source

TMEM92 shields DDX3X from TTC3‐mediated degradation to confer chemoresistance in triple‐negative breast cancer

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
TMEM92 protects DDX3X from degradation by the E3 ligase TTC3, promoting TNBC cell proliferation and tumour growth. Depleting TMEM92 not only suppresses tumour growth but also sensitises cells to cisplatin, suggesting that targeting this axis is a potential therapeutic strategy.
Hao Shen, Xiaochao Jia, Xu Li, Zhi Li, Zhihua Zhang, Yang Zhao, Lei Shen, Xiaoqiu Bu, Qiang Ma, Chunli Liang, Xiaoti Lin, Lin‐Xiaoxi Ma, Chuan Qin   +12 more
wiley   +1 more source

DNA Copy Number Profiling in Extracellular Vesicles as Clinical Biomarkers of High‐Grade Serous Ovarian Carcinoma

Journal of Extracellular Vesicles, Volume 15, Issue 5, May 2026.
ABSTRACT Extracellular vesicles (EVs), including exosomes, circulate in body fluids and carry pathological genomic information. High‐grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian cancer, characterized predominantly by copy number variations (CNVs).
Ryosuke Uekusa, Akira Yokoi, Mayu Ukai, Kosuke Yoshida, Kunanon Chattrairat, Takao Yasui, Yasuhide Inokuma, Masami Kitagawa, Eri Asano‐Inami, Masato Yoshihara, Satoshi Tamauchi, Nobuhisa Yoshikawa, Kaoru Niimi, Juntaro Matsuzaki, Takahiro Ochiya, Anil K. Sood, Yusuke Yamamoto, Hiroaki Kajiyama   +17 more
wiley   +1 more source